7 months ago
3
Generic drugmaker Lupin has launched Rivaroxaban for Oral Suspension, 1 mg/mL, successful the U.S.
The merchandise is bioequivalent to Xarelto for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc. Rivaroxaban for Oral Suspension, 1 mg/mL (reference listed cause Xarelto) had estimated yearly income of $11 cardinal successful the U.S., Lupin said, citing IQVIA MAT July 2025 numbers.
Rivaroxaban for Oral Suspension is indicated for attraction of venous thromboembolism (VTE) and simplification successful the hazard of recurrent VTE successful paediatric patients from commencement to little than 18 years aft astatine slightest 5 days of archetypal parenteral anticoagulant treatment; and attraction of thromboprophylaxis successful pediatric patients 2 years and older with congenital bosom illness aft the Fontan procedure, it said.
